GlassScriptPhysician profile
Carolyn Forbes
NPI 1144251711
$7,122.36
in general payments reported to CMS, 2019-2025
48 companies · $907 in 2025
The $907 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $981 · 2020: $1,125 · 2021: $359 · 2022: $1,165 · 2023: $1,453 · 2024: $1,132 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.50 | 2019-2025 | |
| Medtronic Minimed, INC. | $961.98 | 2019-2020 | |
| Mylan Specialty L.P. | $630.78 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $448.41 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $413.16 | 2022-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.67 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $328.14 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $267.37 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Viatris Specialty LLC | $242.77 | 2025 | Yupelri |
| Astellas Pharma US INC | $242.22 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $183.52 | 2019-2025 | Farxiga, Airsupra |
| Medtronic, INC. | $172.91 | 2022-2025 | Minimed 780g, Intellis Adaptivestim, Minimed 770g |
| Merck Sharp & Dohme LLC | $164.67 | 2019-2023 | Vaxneuvance, Proquad, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $144.47 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.19 | 2022-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Forbes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.